284 related articles for article (PubMed ID: 33804206)
1. Construction and Immunological Evaluation of an Adenoviral Vector-Based Vaccine Candidate for Lassa Fever.
Wang M; Li R; Li Y; Yu C; Chi X; Wu S; Liu S; Xu J; Chen W
Viruses; 2021 Mar; 13(3):. PubMed ID: 33804206
[TBL] [Abstract][Full Text] [Related]
2. Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs.
Maruyama J; Mateer EJ; Manning JT; Sattler R; Seregin AV; Bukreyeva N; Jones FR; Balint JP; Gabitzsch ES; Huang C; Paessler S
Vaccine; 2019 Oct; 37(45):6824-6831. PubMed ID: 31561999
[TBL] [Abstract][Full Text] [Related]
3. A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.
Cai Y; Ye C; Cheng B; Nogales A; Iwasaki M; Yu S; Cooper K; Liu DX; Hart R; Adams R; Brady T; Postnikova EN; Kurtz J; St Claire M; Kuhn JH; de la Torre JC; Martínez-Sobrido L
mBio; 2020 Feb; 11(1):. PubMed ID: 32098811
[TBL] [Abstract][Full Text] [Related]
4. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.
Branco LM; Grove JN; Geske FJ; Boisen ML; Muncy IJ; Magliato SA; Henderson LA; Schoepp RJ; Cashman KA; Hensley LE; Garry RF
Virol J; 2010 Oct; 7():279. PubMed ID: 20961433
[TBL] [Abstract][Full Text] [Related]
5. Current research for a vaccine against Lassa hemorrhagic fever virus.
Warner BM; Safronetz D; Stein DR
Drug Des Devel Ther; 2018; 12():2519-2527. PubMed ID: 30147299
[TBL] [Abstract][Full Text] [Related]
6. An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.
Hashizume M; Takashima A; Iwasaki M
J Virol; 2024 Jun; 98(6):e0057824. PubMed ID: 38767352
[TBL] [Abstract][Full Text] [Related]
7. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.
Cai Y; Iwasaki M; Motooka D; Liu DX; Yu S; Cooper K; Hart R; Adams R; Burdette T; Postnikova EN; Kurtz J; St Claire M; Ye C; Kuhn JH; Martínez-Sobrido L; de la Torre JC
mBio; 2020 Mar; 11(2):. PubMed ID: 32209677
[TBL] [Abstract][Full Text] [Related]
8. An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions.
Li Q; Liu Q; Huang W; Wu J; Nie J; Wang M; Zhao C; Zhang L; Wang Y
Vaccine; 2017 Sep; 35(38):5172-5178. PubMed ID: 28797730
[TBL] [Abstract][Full Text] [Related]
9. Vaccine platforms to control Lassa fever.
Lukashevich IS; Pushko P
Expert Rev Vaccines; 2016 Sep; 15(9):1135-50. PubMed ID: 27136941
[TBL] [Abstract][Full Text] [Related]
10. Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins.
Wang M; Jokinen J; Tretyakova I; Pushko P; Lukashevich IS
Vaccine; 2018 Jan; 36(5):683-690. PubMed ID: 29287681
[TBL] [Abstract][Full Text] [Related]
11. Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.
Abreu-Mota T; Hagen KR; Cooper K; Jahrling PB; Tan G; Wirblich C; Johnson RF; Schnell MJ
Nat Commun; 2018 Oct; 9(1):4223. PubMed ID: 30310067
[TBL] [Abstract][Full Text] [Related]
12. The search for animal models for Lassa fever vaccine development.
Lukashevich IS
Expert Rev Vaccines; 2013 Jan; 12(1):71-86. PubMed ID: 23256740
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques.
Jiang J; Banglore P; Cashman KA; Schmaljohn CS; Schultheis K; Pugh H; Nguyen J; Humeau LM; Broderick KE; Ramos SJ
Hum Vaccin Immunother; 2019; 15(9):2066-2074. PubMed ID: 31071008
[TBL] [Abstract][Full Text] [Related]
14. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
[TBL] [Abstract][Full Text] [Related]
15. Advanced vaccine candidates for Lassa fever.
Lukashevich IS
Viruses; 2012 Oct; 4(11):2514-57. PubMed ID: 23202493
[TBL] [Abstract][Full Text] [Related]
16. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.
Carnec X; Mateo M; Page A; Reynard S; Hortion J; Picard C; Yekwa E; Barrot L; Barron S; Vallve A; Raoul H; Carbonnelle C; Ferron F; Baize S
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593043
[TBL] [Abstract][Full Text] [Related]
17. Vaccine platforms for the prevention of Lassa fever.
Purushotham J; Lambe T; Gilbert SC
Immunol Lett; 2019 Nov; 215():1-11. PubMed ID: 31026485
[TBL] [Abstract][Full Text] [Related]
18. T cell-dependence of Lassa fever pathogenesis.
Flatz L; Rieger T; Merkler D; Bergthaler A; Regen T; Schedensack M; Bestmann L; Verschoor A; Kreutzfeldt M; Brück W; Hanisch UK; Günther S; Pinschewer DD
PLoS Pathog; 2010 Mar; 6(3):e1000836. PubMed ID: 20360949
[TBL] [Abstract][Full Text] [Related]
19. Identification of Common CD8
Sakabe S; Hartnett JN; Ngo N; Goba A; Momoh M; Sandi JD; Kanneh L; Cubitt B; Garcia SD; Ware BC; Kotliar D; Robles-Sikisaka R; Gangavarapu K; Branco LM; Eromon P; Odia I; Ogbaini-Emovon E; Folarin O; Okogbenin S; Okokhere PO; Happi C; Sabeti PC; Andersen KG; Garry RF; de la Torre JC; Grant DS; Schieffelin JS; Oldstone MBA; Sullivan BM
J Virol; 2020 Jun; 94(12):. PubMed ID: 32269122
[TBL] [Abstract][Full Text] [Related]
20. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
Bredenbeek PJ; Molenkamp R; Spaan WJ; Deubel V; Marianneau P; Salvato MS; Moshkoff D; Zapata J; Tikhonov I; Patterson J; Carrion R; Ticer A; Brasky K; Lukashevich IS
Virology; 2006 Feb; 345(2):299-304. PubMed ID: 16412488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]